News About: Pharm. Affairs
Despite clearing the cardiovascular dishonor, Avandia will be voluntarily withdrawn
Avandia(rosiglitazone), a thiazolidinediones(TZD) diabetes drug, was able to avoid the issue of having cardiovascular side effects, but decided to withdraw the domestic market, though.
It seems very contrary to other...
It’s been 10 years for Forsteo without insurance benefit
Will the unfortunate osteoporosis treatment, ‘Forsteo(teriparatide)’ succeed in getting the health insurance benefit?
Since Lilly, a supplier of Forsteo, has taken the re-deliberation process, the government is curre...
First domestically-manufactured cholera vaccine acquiring WHO PQ license
On the 23rd, the Ministry of Food and Drug Safety(Minister Seung-hee Kim, MFDS) announced ‘Euvichol,’ a cholera vaccine that are being domestically manufactured, acquired the WHO’s requalification(PQ) license for the ...
‘Botox’ and ‘Filler’ leading the local clinic market
It was a year with unusually fierce competition between Botox and Filler. The reason why the year was attracting was because domestic products have occupied the local clinic market over products of competitive multina...
Oral antirheumatic ‘Xeljanz’ settles the Big 4 hospitals in 9 months
Pfizer Pharmaceuticals Korea’s ‘Xeljanz(generic name: tofacitinib),’ an oral rheumatoid arthritis treatment, has been safely landed in the Big 4 hospitals within 9 months of the launch on March.
According to the medi...
‘Champix,’ beneficiary of the governmental antismoking support business, increases quadruple in prescriptions
Since the government’s antismoking support business was invigorated this year, the market of antismoking treatments has grown significantly.
The product which led the growth was ‘Champix(varenicline),’ a Pfizer’s ant...
5,705 cases of patent application for pharmaceutical products this year, increased by 19.2%
The number of pharmaceutical patent applications was 5,705 cases, and it was observed to increase 19.2% year-on-year.
According to the data aggregated by the Korean Intellectual Property Office(Director Dong-gyu Choi...
‘Santen vs. Allergan’ for the top in the xerophthalmia market
The xerophthalmia market is experiencing an upheaval. While the 2-strong formation is set among the two originals, the competition for the top is getting fiercer as ‘Diquas’ is about to take over the leading position....
Cialis cut in half in 3 months, caught up by a generic
It has been 3 months Cialis(generic name: tadalafil), an erectile dysfunction treatment, was expired in patent(4 September). Due to aggressiveness of generics, the prescription performance of the original cut in half....
Fierce competition between Chong Kun Dang’s ‘Cemdom’ vs Hanmi Pharm’s ‘Gugu’In the ‘Cialis Generic’ competition, also known as the ‘Generic War’ among domestic pharmaceutical companies, Chong Kun Dang’s ‘Cendom’ and Hanmi Pharm’s ‘Gugu’ have created fie...
|
